Las muestras se recogieron en viales de citología líquida (Preservcyt, Cytyc Corporation, Boxborough, MA) y se almacenaron dos meses a 4 °C hasta su estudio con las dos técnicas, cobas y HC2 (HPV Hybrid Capture Test, Digene, Gaithersburg, USA). El cobas es un sistema totalmente automatizado de The performance of Roche Cobas HPV test was validated and compared with Digene Hybrid Capture 2 (HC2) high-risk HPV DNA test for primary The HPV assay actually in use is the clinically validated cobas HPV test (Roche Diagnostics) [10, 11], run on the cobas system. More recently, a new version of the assay (cobas / HPV) for use on the cobas and cobas systems [ 12 ] has been developed and CE/IVD Enabling the personalization and standardization of your lab’s processes, Roche helps you achieve consistent results quickly across the whole cobas ® platform of analyzers. In addition, Roche provides an extensive and expanding clinical chemistry and immunochemistry test menu so you can help provide patients with the results We conducted a comparison study, according to the international guidelines, nested within the organized population-based cervical screening program, between the High-risk human papillomavirus (HR-HPV) testing has become an increasing important strategy in primary cervical cancer screening in recent years. It warrants the evaluation of molecular-based HPV tests for accuracy and efficacy of screening. The performance of Roche Cobas HPV test was validated and
La prueba del VPH cobas de Roche recibe la aprobación de la …
We used the fully-automated real-time PCR-based cobas ® HPV assay (Roche, Switzerland) for HPV detection and genotyping. The assay can detect HPV16, HPV18, and the pooled presence of twelve other HR-HPVs (HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The performance of Cobas HPV test for Der qualitative cobas® SARS-CoV-2 Test ist ein Doppel-Target Test. Mit nur einem Reaktionsansatz weist er spezifisch SARS-CoV-2 sowie die pan-Sarbecovirus Familie nach zu der auch SARS-CoV-2 gehört. Der Assay verfügt über eine negative, eine positive und eine interne Kontrolle. Die Negativkontrolle umfasst die gesamte Der direkte Nachweis von 14 Hochrisiko HPV mit dem cobas ® HPV Test verbessert die Vorsorge durch sichere, klinisch relevante Ergebnisse und bietet klare Aussagen im Patientenmanagement. Die cobas ® HPV Tests sind qualitative in vitro Tests zum PCR-basierten Nachweis der DNA von Humanen Papillomviren (HPV) in Das cobas ® System automatisiert Ihren Workflow dort, wo Sie es am meisten benötigen. Keine Reagenzvorbereitung (Ready-to-Use), kein manuelles Proben-Scanning, keine manuelle Datenerfassung. Durch das robuste Design des cobas ® Systems verringert sich der tägliche Wartungsaufwand auf ca. vier Minuten, The cobas® SARS-CoV-2 Test is a single-well dual target assay, which includes both specific detection of SARS-CoV-2 and pan-Sarbecovirus detection for the Sarbecovirus subgenus family that includes SARS-CoV The assay has a full-process negative control, positive control and internal control. Two kit sizes ¨High sensitivity and specificity rates of cobas®HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting¨, Rygaard C, et [HOST]ence of human papillomavirus in 5, consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. Plos One The novel cobas HPV test is similar to the cobas HPV test in that it uses real-time PCR to detect the presence of the same 14 HPV types with the same partial genotyping. The main difference is that the assay is of a shorter duration by over an hour (final run time, h), which indicates that changes have been Cobas® HPV Test: Delivering confidence with 3-in-1 HPV test results. The link between cervical cancer and Human Papillomavirus (HPV) has become clear over the past few
Cobas® MTB - Roche Diagnostics USA
Cobas® pure integrated solutions is the newest member of the cobas® family of systems which is designed to deliver excellence, while at the same time simplifying your daily work. cobas® pure combines clinical chemistry, immunochemistry and ISE testing on a footprint of ~21 square feet, giving access to our broad menu of more Nov. 6, —Roche announced that the FDA has approved the Cobas HPV test for use on its next-generation Cobas molecular instrument. The HPV test is indicated for Roche Cobas HPV test (Roche Molecular Systems, Pleasanton, USA) detects HPV16 and HPV18 genotypes in addition to 12 other HR-HPVs, as additional The performance of Roche Cobas HPV test was validated and compared with Digene Hybrid Capture 2 (HC2) high-risk HPV DNA test for primary screening in a large Chinese screening cohort. Of women screened, overall agreement between Cobas and HC2 was % (95% CI: –). The